Covetrus (CVET) Stock Price

Covetrus Price

Delisted

Revenue has compounded at 7.4% per year over the past 6 years to 4.58 B USD. Earnings per share have grown at 19.8% per year over the last 2 years. Covetrus's net margin stands at -1.2%, down from 1.8% several years earlier.

Covetrus stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Covetrus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Covetrus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Covetrus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Covetrus Stock Price History
DateCovetrus Price
Access this data via the Eulerpool API

Covetrus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
3.98 B USD
-997.00 M USD
-1.02 B USD
Jan 1, 2020
4.34 B USD
-69.00 M USD
-19.00 M USD
Jan 1, 2021
4.58 B USD
-22.00 M USD
-54.00 M USD
Jan 1, 2022 (e)
4.80 B USD
239.81 M USD
152.07 M USD
Jan 1, 2023 (e)
5.09 B USD
274.14 M USD
176.73 M USD
Jan 1, 2024 (e)
5.56 B USD
301.96 M USD
193.40 M USD
Jan 1, 2025 (e)
5.79 B USD
332.25 M USD
214.64 M USD
Jan 1, 2026 (e)
6.14 B USD
372.89 M USD
242.99 M USD

Covetrus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 26, 2026, 10:15 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022e2023e2024e2025e2026e
2.983.353.583.783.984.344.584.805.095.565.796.14
12.596.745.535.279.135.444.856.009.324.106.17
17.8018.4618.2218.1118.8418.3918.7518.7518.7518.7518.7518.75
0.530.620.650.680.750.800.860.900.951.041.091.15
103.00123.00135.00137.00-997.00-69.00-22.00239.00274.00301.00332.00372.00
3.463.673.773.63-25.08-1.59-0.484.985.395.415.746.05
0.060.070.060.10-1.02-0.02-0.050.150.180.190.210.24
16.67-8.5756.25-1,119.00-98.14184.21-381.4815.799.6610.8813.08
137.0072.0072.0072.00107.00118.00137.00137.00137.00137.00137.00137.00
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Covetrus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Covetrus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Covetrus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Covetrus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Covetrus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Covetrus stock margins

The Covetrus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Covetrus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Covetrus.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
18.21 %
3.78 %
1.80 %
Jan 1, 2018
18.11 %
3.63 %
2.67 %
Jan 1, 2019
18.84 %
-25.08 %
-25.63 %
Jan 1, 2020
18.39 %
-1.59 %
-0.44 %
Jan 1, 2021
18.75 %
-0.48 %
-1.18 %
Jan 1, 2022 (e)
18.75 %
5.00 %
3.17 %
Jan 1, 2023 (e)
18.75 %
5.39 %
3.48 %
Jan 1, 2024 (e)
18.75 %
5.43 %
3.48 %

Covetrus Stock Revenue, EBIT, Earnings per Share

The Covetrus earnings per share therefore indicates how much revenue Covetrus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
49.72 USD
1.88 USD
0.89 USD
Jan 1, 2018
52.47 USD
1.90 USD
1.40 USD
Jan 1, 2019
37.16 USD
-9.32 USD
-9.52 USD
Jan 1, 2020
36.77 USD
-0.58 USD
-0.16 USD
Jan 1, 2021
33.39 USD
-0.16 USD
-0.39 USD
Jan 1, 2022 (e)
35.02 USD
1.75 USD
1.11 USD
Jan 1, 2023 (e)
37.12 USD
2.00 USD
1.29 USD
Jan 1, 2024 (e)
40.58 USD
2.20 USD
1.41 USD

Covetrus business model & stock analysis

Covetrus Inc is a global company specializing in providing services and products for veterinarians, animal clinics, and pet owners. It was formed in 2019 through a merger between the animal health divisions of Henry Schein and Vets First Choice. Covetrus traces its history back to 1856 when Henry Schein was founded as a small wholesale drug company. Over the years, the company expanded into new industries and markets. In the 2000s, Henry Schein began serving the animal health industry and established Vets First Choice in 2010 to offer a wider range of services and products to veterinarians and animal clinics. With the merger of Vets First Choice and Henry Schein's animal health division in 2019, Covetrus was created as a company with a broad spectrum of products and services for the animal health industry. Covetrus is headquartered in Portland, Maine, USA, and operates in over 25 countries. Its business model is based on providing services and products for veterinarians, animal clinics, and pet owners. The company is divided into several business segments, including diagnostics, pharmaceuticals, and consumables. In the diagnostics area, Covetrus offers a wide range of laboratory diagnostic services for veterinarians, including blood tests, imaging, fecal tests, and genetic tests. These test results help veterinarians diagnose and treat diseases in pets. In the pharmaceutical area, Covetrus offers veterinary medicines for various types of pets, including dogs, cats, and horses. These medicines are developed by leading pharmaceutical companies, and Covetrus provides veterinarians with a reliable supply chain for these products. The most recent business segment of Covetrus is the consumables area. Here, the company offers a wide range of products for veterinarians and animal clinics, including medical devices, surgical instruments, consumables for routine examinations, and more. In addition to these three main business segments, Covetrus also offers a variety of services, including practice management systems, training for veterinarians and animal clinics, financial services, and more. These services are designed to help veterinarians and animal clinics optimize their operations and improve their quality. The company has also developed a mobile application called 'Covetrus Connect' which provides veterinarians and animal clinics with an easier way to access products and services, place orders, and manage their operations. Overall, Covetrus is an innovative and rapidly growing company in the animal health industry. With a wide range of products and services tailored to the needs of veterinarians, animal clinics, and pet owners, the company is well-positioned to continue growing in this emerging market.

Covetrus SWOT Analysis

Strengths

1. Market Leader: Covetrus Inc is one of the leading companies in the animal health technology and services industry, enjoying a significant market share.

2. Global Presence: The company operates in multiple countries, allowing it to reach a wide customer base worldwide.

Weaknesses

1. Dependency on Veterinary Practices: Covetrus Inc heavily relies on partnerships with veterinary practices for its revenue, making it susceptible to changes in their business models or declining demand.

2. Limited Product Portfolio: The company's product offerings are primarily focused on animal health technology and services, which may restrict its growth potential compared to companies with more diversified portfolios.

Opportunities

1. Growing Pet Industry: The increasing pet ownership and demand for related products and services present an opportunity for Covetrus Inc to expand its customer base and revenue.

2. Technological Advancements: Embracing emerging technologies in the animal health sector, such as telemedicine and digital healthcare solutions, can help Covetrus Inc enhance its offerings and stay ahead of competitors.

Threats

1. Intense Competition: The animal health technology and services industry is competitive, with the presence of established players and new entrants. Covetrus Inc needs to continually innovate and differentiate itself to maintain a competitive edge.

2. Regulatory Challenges: Compliance with regulatory requirements in various markets can pose challenges for Covetrus Inc, requiring significant investments and resources.

Covetrus Segments

Covetrus Revenue by Segment

  • 3 Years

  • 5 Years

  • Max

North America
Europe
APAC & Emerging Markets
Details
Date
North America
Europe
APAC & Emerging Markets
Jan 1, 2019
2.11 B USD
1.51 B USD
368.00 M USD
Jan 1, 2020
2.38 B USD
1.57 B USD
402.00 M USD
Jan 1, 2021
2.72 B USD
1.41 B USD
461.00 M USD

Covetrus Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Covetrus historical P/E ratio, EBIT multiple, and P/S ratio

Covetrus annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Covetrus shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
72.00 M Stocks
Jan 1, 2018
72.00 M Stocks
Jan 1, 2019
107.00 M Stocks
Jan 1, 2020
118.00 M Stocks
Jan 1, 2021
137.00 M Stocks
Jan 1, 2022 (e)
137.00 M Stocks
Jan 1, 2023 (e)
137.00 M Stocks
Jan 1, 2024 (e)
137.00 M Stocks
Price targets and forecasts for Covetrus are not yet available.

Covetrus Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/2/20230.30USD1.31 BUSD2023 Q2
5/3/20230.28USD1.23 BUSD2023 Q1
2/22/20230.29USD1.24 BUSD2022 Q4
11/29/20220.27USD1.26 BUSD2022 Q3
8/4/20220.26USD1.24 BUSD2022 Q2
5/5/20220.23USD1.16 BUSD2022 Q1
2/24/20220.25USD1.15 BUSD2021 Q4
11/4/20210.23USD1.18 BUSD2021 Q3
8/5/20210.24USD1.13 BUSD2021 Q2
5/6/20210.17USD1.10 BUSD2021 Q1

Covetrus shareholder structure

% Name
24.62212%
Clayton, Dubilier & Rice, LLC
Clayton, Dubilier & Rice, LLC
11.54392%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
8.50921%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.11161%
Wellington Management Company, LLP
Wellington Management Company, LLP
2.83096%
State Street Global Advisors (US)
State Street Global Advisors (US)
2.25156%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Covetrus Executives and Management Board

BW

Mr. Benjamin Wolin

(47)

President, Chief Executive Officer, Director · since 2019

Compensation6.52 M USD
MM

Mr. Matthew Malenfant

(60)

Chief Commercial Officer

Compensation2.73 M USD
MF

Mr. Matthew Foulston

(58)

Chief Financial Officer, Executive Vice President

Compensation2.52 M USD
GW

Ms. Georgina Wraight

(47)

Executive Vice President, President - Global Technology Solutions

Compensation1.76 M USD
DF

Mr. Dustin Finer

(52)

Chief Administrative Officer

Compensation1.55 M USD

Frequently asked questions about Covetrus

The business model of Covetrus Inc is to provide technology-enabled services and solutions for the veterinary market. As a leading global animal health technology and services company, Covetrus offers a comprehensive suite of software, pharmacy, and supply chain solutions for veterinary practices, clinics, and hospitals. By harnessing the power of technology, Covetrus aims to enhance patient care, improve practice efficiency, and streamline the veterinary supply chain. With a strong focus on innovation and customer-centric offerings, Covetrus continues to empower veterinary professionals with advanced tools and resources to deliver quality care to animals worldwide.

All fundamentals and in-depth analysis of Covetrus

Our stock analysis for Covetrus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Covetrus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.